EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-Tkis) represented by gefitinib have shown good efficacy as adjuvant therapy for early NSCLC patients with EGFR-sensitized mutations (Ye et al., 2021).